Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 9Phase 1/2 6Phase NA 2Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 3Nasopharyngeal Carcinoma 3Recurrence 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Thromboembolism 1Stomach Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1Malnutrition 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Locally Advanced Pancreatic Cancer 1Infiltrating Bladder Urothelial Carcinoma 1Immunoblastic Lymphadenopathy 1Hypoxia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 2chondroitin sulfate, sodium hyaluronate drug combination 1Water 1Therapeutics 1Radiotherapy 1Multiparametric Magnetic Resonance Imaging 1Mitomycin 1Hyaluronic Acid 1Epirubicin 1Docetaxel 1Chondroitin Sulfates 1Anesthesia, Spinal 1Anesthesia, General 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Non-Muscle Invasive Bladder Neoplasms × Gemcitabine × Clear all
NCT05671900 2024-03-08

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Clinical Hospital Centre Zagreb

Phase NA Unknown
70 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05626101 2024-02-13

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Al-Azhar University

Phase NA Unknown
280 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡